Kesimpta effective up to six years

Novartis (NOVN: VX) has announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta (ofatumumab) treatment for up to six years in recently diagnosed treatment-naïve people living with relapsing multiple sclerosis (RMS).

These efficacy outcomes included 44% fewer relapses, 96.4% and 82.7% reductions in MRI lesions, respectively, and 24.5% and 21.6% fewer three- and six-month confirmed disability worsening events, respectively, versus those who switched to Kesimpta from teriflunomide.

"Adds to the growing body of evidence of Kesimpta as an efficacious and well-tolerated option"A separate analysis of the overall ALITHIOS population showed similar efficacy with continuous Kesimpta treatment, which was also well-tolerated with a consistent safety profile up to six years. These data are being presented at the ongoing American Academy of Neurology (AAN) 2024 Annual Meeting held in Denver, Colorado, USA.